(Q33887804)

29 July 2017

Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry (English)

1 reference

29 July 2017

0 references

T Buchler

1

0 references

author name string

R Klapka

2

1 reference

29 July 2017

B Melichar

3

1 reference

29 July 2017

P Brabec

4

1 reference

29 July 2017

L Dusek

5

1 reference

29 July 2017

R Vyzula

6

1 reference

29 July 2017

J Abrahamova

7

1 reference

29 July 2017

2 May 2011

1 reference

29 July 2017

1 reference

29 July 2017

23

1 reference

29 July 2017

395-401

1 reference

29 July 2017

2

1 reference

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

29 July 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR065

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR065

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR065

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR065

Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR065

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR065

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR065

Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR065

Sequential sorafenib and sunitinib for renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR065

Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR065

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR065

Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR065

How can second-line therapy for metastatic renal cell carcinoma help to define an overall management strategy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR065

A quantitative analysis of kinase inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR065

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR065

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDR065

1 reference

29 July 2017

1 reference